Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2016', provides in depth analysis on Glucagon Like Peptide 2 Receptor (GLP2R) targeted pipeline therapeutics. The report provides comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R) - The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects - The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Glucagon Like Peptide 2 Receptor (GLP2R) Overview 6 Therapeutics Development 7 Glucagon Like Peptide 2 Receptor (GLP2R) - Products under Development by Stage of Development 7 Glucagon Like Peptide 2 Receptor (GLP2R) - Products under Development by Therapy Area 8 Glucagon Like Peptide 2 Receptor (GLP2R) - Products under Development by Indication 9 Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Glucagon Like Peptide 2 Receptor (GLP2R) - Products under Development by Companies 12 Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development 19 Naia Limited 19 Shire Plc 20 Tasly Pharmaceutical Group Co., Ltd. 21 Zealand Pharma A/S 22 Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles 23 FE-203799 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 glepaglutide - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 GXG-8 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 NB-1002 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 teduglutide - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 ZPGG-23 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 ZPGG-72 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Projects 35 Glucagon Like Peptide 2 Receptor (GLP2R) - Featured News & Press Releases 36 Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS) 36 May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome 37 Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 38 Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome 38 Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX 39 Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan 39 Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data 40 Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association's (ADA) 74th Scientific Sessions 41 Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome 41 Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection 42 Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome 43 Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting 44 Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome 45 Jan 02, 2013: ThriveRx Receives Limited Distribution Rights To NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome In Adults 47 Dec 27, 2012: Coram Specialty Infusion Services To Provide NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome 47 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 15 Number of Products by Stage and Route of Administration, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Naia Limited, H2 2016 19 Pipeline by Shire Plc, H2 2016 20 Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016 21 Pipeline by Zealand Pharma A/S, H2 2016 22 Dormant Projects, H2 2016 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
